| EGF-ERBB2-RAS-ERK signaling pathway |
| Amplified ERBB2 to RAS-ERK signaling pathway |
| FGF-FGFR-RAS-ERK signaling pathway |
| Amplified FGFR to RAS-ERK signaling pathway |
| HGF-MET-RAS-ERK signaling pathway |
| Amplified MET to RAS-ERK signaling pathway |
| Mutation-activated KRAS/NRAS to ERK signaling pathway |
| AREG-EGFR-PI3K signaling pathway |
| Amplified ERBB2 to PI3K signaling pathway |
| FGF-FGFR-PI3K signaling pathway |
| Amplified FGFR to PI3K signaling pathway |
| HGF-MET-PI3K signaling pathway |
| Amplified MET to PI3K signaling pathway |
| Wnt signaling pathway |
| Mutation-inactivated APC to Wnt signaling pathway |
| Loss of CDH1 to beta-catenin signaling pathway |
| Mutation-inactivated CDH1 to beta-catenin signaling pathway |
| TGF-beta signaling pathway |
| TGFBR1-reduced expression to TGF-beta signaling pathway |
| p27-Cell cycle G1/S |
| CDKN1B-reduced expression to p27-cell cycle G1/S |
| Amplified CCNE to cell cycle G1/S |
| Telomerase activity |
| TERT-overexpression to telomerase activity |
| Mutation-inactivated TP53 to transcription |
| CDX2-overexpression to transcriptional activation |
| CDX2-overexpression to transcriptional repression |